Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

International Salmonella Typhimurium DT104 Infections, 1992–2001

Morten Helms*Comments to Author , Steen Ethelberg*, Kåre Mølbak*, and the DT104 study group
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark

Main Article

Figure 3

Multidrug-resistant Salmonella enterica serovar Typhimurium as a percentage of all S. Typhimurium in 9 world regions, 1992–2001. Only countries that had data available for 2 or more 2-year periods are included: United Kingdom and Ireland: Scotland and Ireland; Scandinavia and the Baltics: Denmark, Finland, Norway, and Latvia; Western Europe: Austria, Germany, Luxembourg, and the Netherlands; Eastern Europe: Czech Republic and Hungary; Southern Europe: Greece, Malta, and Spain; North America: Can

Figure 3. . Multidrug-resistant Salmonella enterica serovar Typhimurium as a percentage of all S. Typhimurium in 9 world regions, 1992–2001. Only countries that had data available for 2 or more 2-year periods are included: United Kingdom and Ireland: Scotland and Ireland; Scandinavia and the Baltics: Denmark, Finland, Norway, and Latvia; Western Europe: Austria, Germany, Luxembourg, and the Netherlands; Eastern Europe: Czech Republic and Hungary; Southern Europe: Greece, Malta, and Spain; North America: Canada, United States; South America: Brazil; Eastern Asia: the Republic of Korea; Oceania: Australia.

Main Article

1Data for this survey were contributed by the DT104 study group, which consisted of the following: Diane Lightfoot and J. Powling, Australia; Christian Berghold and Christian Kornshober, Austria; Ingrid Wybo, J.M. Collard, and C. Godard, Belgium; Dalia dos Prazeres Rodrigues, Eliane Moura Falavina dos Reis, and Erica L. Fonseca, Brazil; Kathryn Doré, James Flint, Frank Pollari, Rafiq Ahmed, and Walter Demczuk, Canada; James Hospedales, Denise Clarke, and Michelle Nurse-Lucas, Caribbean Region; Renata Karpiskova, The Czech Republic; Peter Gerner-Smidt, Denmark; Noël Gill, Sarah O'Brien, and John Threlfall, England and Wales; Anja Siitonen and Susanna Lukinmaa, Finland; Wolfgang Rabsch, Germany; Panayotis T. Tassios, Leonidas S. Tzouvelekis, and Takis Panagiotopoulos, Greece; Judit Pàszti and Noelni Nógrády, Hungary; Barbara Foley, Martin Cormican, and Paul McKeown, Ireland; Nahum Andorn and Ruti Yishai, Israel; Haruo Watanabe and Hidemasa Izumiya, Japan; Bok Kwon Lee and Shukho Kim, Republic of Korea; J. Selga and J. Jansone, Latvia; Joel Mossong and François Schneider, Luxembourg; Julie Haider and Paul Cuschieri, Malta; Wilfrid van Pelt, Netherlands; Helen Heffernan and Carolyn Nicol, New Zealand; Karin Nygård and Trine Lise Stavnes, Norway; B.L. Cherkasskiy, Russian Federation; Lynda Browning and John Coia, Scotland; Karen Helena Keddy and Tersia Kruger, Republic of South Africa; Miquel Anger Usera, Spain; Agneta Olsson, Sweden; Patrick Boerlin, Switzerland; Timothy Barrett, Frederick J. Angulo, and Jennifer E. Stevenson, USA.

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external